Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.30 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL30455914 | 0.87 | CA4 (0.38) | CA4BBOX1TSHRTP53EGLN1 | |
| SCHEMBL31121005 | 0.85 | CA4 (0.39) | CA4BBOX1 | |
| SCHEMBL31596793 | 0.83 | CA4 (0.35) | CA4BBOX1 | |
| SCHEMBL29970296 | 0.83 | CA4 (0.35) | CA4BBOX1 | |
| SCHEMBL30758921 | 0.82 | CA4 (0.37) | CA4BBOX1 | |
| SCHEMBL29777402 | 0.79 | CA4 (0.41) | CA4BBOX1 | |
| SCHEMBL31151780 | 0.79 | GLA (0.42) | TSHR | |
| SCHEMBL30402594 | 0.78 | CA4 (0.39) | CA4 | |
| SCHEMBL31621795 | 0.76 | FABP3 (0.43) | — | |
| SCHEMBL29396627 | 0.76 | FABP3 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022081350-A2 | METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES | DUKE UNIVERSITY (US) | 2022-04-21 | — | — | WO | claimed |
| US-20260148848-A1 | BIOMARKERS FOR DIAGNOSIS AND TREATMENT OF ENDOCRINE HYPERTENSION, AND METHODS OF IDENTIFICATION THEREOF | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2026-05-28 | — | — | US | disclosed |
| US-20250314660-A1 | METABOLIC BIOMARKERS FOR ASSESSING FRIEDREICH'S ATAXIA IN A SUBJECT | THE TRUSTEES OF INDIANA UNIVERSITY | 2025-10-09 | — | — | US | disclosed |
| US-20240192216-A1 | METABOLIC BIOMARKER SET FOR ASSESSING OVARIAN CANCER | BIOCRATES LIFE SCIENCES AG (AT) | 2024-06-13 | — | — | US | disclosed |
| EP-3775906-B1 | METABOLITE-BASED BREAST CANCER DETECTION AND DIAGNOSIS | BURWINKEL BARBARA (DE) | 2023-08-30 | — | — | EP | disclosed |
| US-11506665-B2 | Metabolic biomarker set for assessing ovarian cancer | BIOCRATES LIFE SCIENCES AG (AT) | 2022-11-22 | — | — | US | disclosed |
| US-11493516-B2 | Biomarkers for assessing breast cancer | METABOLOMYCS, INC (US) | 2022-11-08 | — | — | US | disclosed |
| EP-2771696-B1 | METHODS MAKING USE OF PANELS OF METABOLITES FOR THE DIAGNOSIS AND DIFFERENTIATION OF NEONATAL ENCEPHALOPATHY | INFANDX AG (DE) | 2022-09-14 | — | — | EP | disclosed |
| US-20220187315-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSING DEPRESSION | DUKE UNIVERSITY | 2022-06-16 | — | — | US | disclosed |
| US-11313866-B2 | Method of diagnosing and treating asphyxia | INFANDX AG (DE) | 2022-04-26 | — | — | US | disclosed |
| WO-2022081350-A2 | METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES | DUKE UNIVERSITY (US) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260148848-A1 | BIOMARKERS FOR DIAGNOSIS AND TREATMENT OF ENDOCRINE HYPERTENSION, AND METHODS OF IDENTIFICATION THEREOF | SHBG, HSD11B2, HSD11B1 | CA4 673/4885BBOX1 1680/4885TSHR 1111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.